# A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

> **NCT03432260** · PHASE2 · COMPLETED · sponsor: **Durect** · enrollment: 19 (actual)

## Conditions studied

- Alcoholic Hepatitis

## Interventions

- **DRUG:** DUR-928 30 mg
- **DRUG:** DUR-928 90 mg
- **DRUG:** DUR-928 150 mg

## Key facts

- **NCT ID:** NCT03432260
- **Lead sponsor:** Durect
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-18
- **Primary completion:** 2019-09-09
- **Final completion:** 2019-09-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03432260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03432260, "A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03432260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*